WASHINGTON—In an effort to address the needs of women suffering from a lack of sexual desire, the FDA announced Tuesday that it had approved a new female-libido-enhancing man, which is expected to be made available to the general public by year’s end. “After conducting numerous trials on hundreds of female subjects with low sex drives, we determined that this man significantly increased sexual interest among women of all ages,” said FDA representative Jane Newlon, who noted that using the 75kg man, known as Gabriel, every day had been shown to activate the regions of the brain associated with pleasure, increase blood flow to the genitals, and boost instances of orgasm by almost 40 percent. “We observed a sharp rise in libido immediately after the man is introduced, with stimulative effects lasting for up to four hours at a time. In a marketplace dominated by male-libido-enhancing products, it is a significant milestone to finally have a safe, effective option for women who want to increase their arousal, and that is exactly what this man offers.” Newlon went on to warn consumers that when mixed with alcohol, the man becomes much less effective.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves first at-home coronavirus test kitWATCH: The FDA has approved the first at-home test kit for coronavirus. 'Under certain circumstances with a doctor's supervision, a test can be mailed to a patient, and the patient can perform the self-swab and then mail it back and get the results.'
Consulte Mais informação »
FDA warns against malaria drug's COVID-19 use outside hospitalsThe U.S. Food and Drug Administration on Friday cautioned against the use of malaria drug hydroxychloroquine, touted by President Donald Trump, in COVID-19 patients outside of hospitals and clinical trials, citing risks of serious heart rhythm problems.
Consulte Mais informação »
FDA warns against using hydroxychloroquine for coronavirus outside of hospitalsNEW: FDA on Friday cautioned against prescribing hydroxychloroquine to COVID-19 patients outside of hospital settings or clinical trials.
Consulte Mais informação »